The Future of Liver Transplantation

Executive Summary

The next decade of liver transplantation is likely to be defined by “active preservation” and “active personalization.” Portable normothermic machine perfusion (NMP) and hypothermic oxygenated perfusion (HOPE/D-HOPE) are already supported by randomized data showing reductions in clinically important endpoints such as early allograft dysfunction (EAD) and non-anastomotic biliary strictures in high-risk grafts. ^{[1] [2]} In parallel, DCD programs are becoming safer through standardized documentation of warm ischemia, protocolized procurement, and growing use of regional perfusion and post-procurement machine perfusion. ^[4] Longer-term, the field is moving toward precision immunosuppression (pharmacogenomics + analytics + biomarker surveillance) and immune modulation that may enable carefully selected patients to reduce maintenance immunosuppression under strict monitoring. ^{[5] [6]}

Key Drivers of Change

1) Donor scarcity and safer expansion

Demand continues to outpace supply, and the system’s response is to expand utilization while keeping outcomes acceptable. This includes broader use of DCD donors, steatotic grafts, and older donors—paired with improved preservation and objective viability assessment. Randomized evidence supporting machine perfusion strengthens the justification for using marginal organs when real-time functional readouts are favorable. ^{[1] [2]}

2) Peri-operative risk reduction

The peri-operative phase remains a major determinant of early outcomes, particularly for marginal grafts. Teams are increasingly using structured approaches to anticipate reperfusion physiology, guide transfusion with viscoelastic testing, and shorten ischemia times through logistics enabled by longer preservation windows. Normothermic perfusion changes the “hand-off” between procurement and implantation from passive cold storage to an active phase where trends (e.g., lactate kinetics) inform accept/decline decisions. ^[1]

3) Long-term morbidity and cumulative toxicity

Chronic calcineurin inhibitor (CNI) exposure contributes to nephrotoxicity, hypertension, diabetes, infection risk, and malignancy, driving interest in CNI minimization, mTOR-based strategies in selected patients, and precision dosing informed by genetics and drug-level analytics. The goal is not “less immunosuppression” indiscriminately, but the lowest effective exposure with early detection of alloimmune activation. ^[5]

4) Equity, access, and data stewardship

Allocation, logistics, and national data definitions influence equity and organ utilization. In the U.S., OPTN initiatives include improving donor/organ data elements (e.g., ischemia metrics and machine perfusion reporting) so outcomes analyses and policy decisions are based on higher-quality, more complete information. ^[11]

Ex-Situ Machine Perfusion

Why perfusion matters

Static cold storage slows metabolism but cannot demonstrate whether a marginal liver will function well after implantation. Perfusion converts preservation into a monitored physiologic interval. With NMP, the liver is supported at near-physiologic temperature with oxygenated perfusate, allowing observable metabolism (e.g., lactate clearance) and bile production. A large multicenter randomized clinical trial (OCS Liver PROTECT) reported improved outcomes including reduced EAD and fewer ischemic biliary complications compared with conventional cold storage. ^[1]

HOPE / D-HOPE for DCD and high-risk grafts

Hypothermic oxygenated perfusion aims to replenish mitochondrial energy stores and mitigate oxidative injury that manifests at reperfusion. In a randomized trial of D-HOPE in DCD livers, hypothermic oxygenated perfusion reduced the risk of non-anastomotic biliary strictures compared with static cold storage, supporting a targeted role in grafts where ischemic cholangiopathy is a central concern. ^[2]

Viability assessment: operationalizing “acceptability”

Centers commonly operationalize NMP viability using a bundle of signals rather than a single number: lactate trend and clearance, perfusate pH stability, vascular flows and resistances, and bile quantity and quality. A critical training point is disciplined interpretation: trends and thresholds must be predefined, documented, and communicated consistently to avoid “drift” across teams and over time. Trials and regulatory-grade datasets increasingly support standardized endpoint definitions (e.g., EAD; ischemic biliary complications) so that local protocols can be benchmarked. ^{[1] [10]}

Optimization of DCD Liver Transplantation

Warm ischemia documentation and procurement rigor

DCD livers expand the donor pool but carry warm-ischemia–related risks, particularly ischemic cholangiopathy and primary non-function. Outcomes correlate with functional warm ischemia duration and quality of donor physiology during the agonal phase. Because definitions vary across centers, standardized documentation is a recurring quality-improvement target, and professional statements provide a framework for controlled DCD processes and terminology. ^{[4] [9]}

Regional perfusion and post-procurement strategies

Programs increasingly combine in-situ approaches (e.g., normothermic regional perfusion in selected settings) with post-procurement ex-situ perfusion (HOPE/NMP), aiming to mitigate ischemia-reperfusion injury and improve biliary outcomes. Perfusion can also provide a decision window: marginal organs can be assessed rather than discarded based on appearance alone. ^[2]

Systems-level improvement: capturing perfusion and ischemia data

Because DCD optimization is protocol-driven, high-quality data capture is essential. OPTN/UNOS initiatives have specifically addressed donor/organ data collection, including machine perfusion elements, to support better measurement of utilization and outcomes. ^[11]

Precision Pharmacology & Immunosuppression

From “trough targets” to individualized exposure

Precision immunosuppression attempts to maintain rejection control while reducing cumulative toxicity. A foundational example is CYP3A5 genotype–guided tacrolimus dosing: CPIC guidance recommends higher starting doses for CYP3A5 expressers (rapid metabolizers), recognizing substantial between-patient variability that otherwise leads to prolonged time-to-therapeutic exposure. ^[5]

Analytics: interaction detection and adaptive monitoring

Clinical reality is dominated by interactions: azole antifungals, macrolides, calcium channel blockers, and other agents can markedly change tacrolimus exposure. Precision practice embeds safety into workflow—standardized interaction checks, predictable lab timing, and rapid dose-response loops—rather than relying on “memory.” Genotype-guided dosing does not replace therapeutic drug monitoring; it is an improved starting point. ^[5]

Biomarkers to reduce uncertainty

Biomarkers are increasingly used to detect alloimmune activation earlier and reduce blind escalation. Donor-derived cell-free DNA (dd-cfDNA) is one such signal; emerging liver-transplant literature describes associations between elevated dd-cfDNA and rejection, with active research on thresholds, timing, and confounders (e.g., infection, ischemic injury). While adoption varies by center, dd-cfDNA illustrates the direction of travel: earlier warning, fewer unnecessary biopsies, and more confident tapering when stable. ^[6]

Immune Modulation & Toward Operational Tolerance

Why the liver is a special “tolerance candidate”

The liver has long been recognized as comparatively tolerogenic among solid organs, which is why operational tolerance (stable graft function with minimal or no maintenance immunosuppression) is a realistic research objective in carefully selected recipients. The strategy requires two capabilities: (1) an intervention that promotes tolerance, and (2) monitoring sensitive enough to detect subclinical alloimmune injury before it becomes irreversible. ^[7]

Cell therapies: regulatory T cells as a leading platform

Regulatory T-cell (Treg) therapy has advanced from concept to clinical trials in liver transplantation. A phase I study reported feasibility and safety signals for adoptive transfer of expanded Tregs in liver transplant recipients, and ongoing registered trials continue to evaluate whether cell therapy can support safe immunosuppression minimization under protocolized surveillance. ^{[7] [8]}

Protocolized tapering and “reversible decisions”

Operational tolerance programs, when pursued, should be slow, rule-based, and reversible—using pre-specified triggers for biopsy and prompt escalation. Patients considered for tapering are typically stable, without recent rejection, and with reassuring histology. The future direction is not “everyone off drugs,” but rather “the right patient, with the right monitoring, tapered safely when biology permits.” ^[7]

AI-Assisted Decision Support Across the Care Continuum

Where AI is already clinically plausible

AI and machine learning have produced useful models for transplant-relevant predictions, including organ utilization and early risk stratification. In liver transplant contexts, published work includes models predicting whether recovered livers will be utilized, suggesting potential applications in donor management and procurement planning. As machine perfusion expands, time-series perfusion data (flows, pressures, lactate kinetics) is a natural substrate for decision support. ^{[13] [14]}

Implementation: workflow, bias, and governance

The limiting factor for AI is rarely model performance alone—it is integration: data quality, validation across diverse populations, and presentation within clinical workflows with transparent rationale. Governance (version control, drift monitoring, and documentation of overrides) is critical in high-stakes decisions such as accept/decline and immunosuppression adjustment. Teams should treat AI as augmentation: a second set of eyes that must be clinically interrogated. ^[14]

Bioengineering: Scaffolds, Organoids, and Bioprinting

Decellularized scaffolds and recellularization

Decellularized liver scaffolds preserve native extracellular matrix and vascular architecture, creating a template for reseeding with hepatocytes and endothelial cells. Persistent challenges include uniform cell distribution, stable endothelialization, bile duct reconstruction, and long-term functional durability under perfusion. Nonetheless, scaffolds remain a credible route to partial graft engineering and to ex-vivo platforms for testing therapies. ^[15]

Organoids and regenerative “bridge” therapies

Liver organoids derived from stem cells or adult progenitors are increasingly used for disease modeling and drug testing, and they represent a potential path toward implantable regenerative therapies. Early clinical translation in other liver indications (e.g., cell-based or tissue-like constructs) informs the liver transplant horizon, where engineered tissue may first appear as adjuncts (bile duct segments, vascular patches, or bridge therapies) rather than full organ replacement. ^[16]

Xenotransplant Research

Gene-edited porcine donors: the leading platform

Xenotransplantation aims to reduce the donor gap using organs from another species, most commonly gene-edited pigs. Modern approaches remove key xenoantigens and add human complement/coagulation regulatory factors to reduce hyperacute and delayed rejection. Infectious safety remains central, including designated pathogen-free breeding and stringent surveillance strategies addressing concerns such as porcine endogenous retroviruses (PERVs). ^{[17] [18]}

Realistic near-term role

In the near term, xenotransplantation is more likely to proceed under tightly regulated research protocols for patients with limited alternatives, with long-term monitoring requirements and independent oversight. Importantly, xenotransplant research can also feed back into allotransplantation—improving understanding of complement/coagulation biology and accelerating novel immunomodulatory strategies. ^[17]

References

1. Markmann JF, et al. Impact of portable normothermic blood-based machine perfusion (OCS Liver) on outcomes: The OCS Liver PROTECT randomized clinical trial. JAMA Surgery. 2022.
2. van Rijn R, et al. Hypothermic oxygenated machine perfusion in liver transplantation (D-HOPE-DCD randomized trial). New England Journal of Medicine. 2021.
3. van Rijn R, et al. Hypothermic Machine Perfusion in Liver Transplantation (abstract record). PubMed. 2021.
4. American Society of Anesthesiologists. Statement on Controlled Organ Donation After Circulatory Death (cDCD) (educational guide/template).
5. CPIC. Guideline for Tacrolimus and CYP3A5 (genotype-guided initial dosing; TDM still required). 2015 (most recent dosing guidance).
6. Julian J, et al. Donor-derived cell-free DNA monitoring in liver transplantation (review/monitoring concepts and associations with rejection). 2025 (PMC full text).
7. Sánchez-Fueyo A, et al. Regulatory T-cell therapy in liver transplantation: phase I trial feasibility/safety and biological activity. PubMed record. 2020.
8. ClinicalTrials.gov. Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplantation (trial registration: NCT02166177).
9. Reich DJ, et al. ASTS recommended practice guidance for controlled DCD (historical framework and terminology). American Journal of Transplantation. 2009.
10. ClinicalTrials.gov. OCS Liver PROTECT Trial study record (NCT02522871) — endpoints and design.
11. HRSA/UNOS. Data Collection to Evaluate Organ Logistics and Allocation — includes liver machine perfusion data elements (PDF). 2021.
12. Wikimedia Commons. “Left Liver Transplant” illustration (CC BY-SA 4.0) — source and license.
13. Bishara AM, et al. Machine learning prediction of liver allograft utilization (Transplantation Direct). 2021.
14. Review: Machine learning / AI in liver transplantation and clinical prediction (Frontiers Partnerships; PMC full text). 2025.
15. Review: Decellularized liver scaffolds and recellularization for bioengineered liver constructs (PubMed record).
16. Review: Liver organoids (iPSC/adult progenitor-derived), translational progress and clinical directions (PMC full text).
17. Review: Recent progress in pig-to-human kidney xenotransplantation (gene-edited pigs, monitoring, infectious risk) — principles relevant to xenotransplant programs.
18. Galli C, et al. Gene editing in pigs for xenotransplantation: current techniques and infectious-risk considerations (Transplant International). 2025.